The U.S. Food and Drug Administration has approved GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adult ...

At ATS 2025, data from the Phase III MATINEE trial reinforced the efficacy of Nucala in reducing exacerbations in COPD ...

GSK respiratory, immunology and inflammation research and development (R&D) global head and senior vice-president Kaivan ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic ...

While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...

The U.S. Food and Drug Administration has approved Nucala as a supplementary treatment for elderly individuals with severe ...

FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...

The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil ...

Nucala, an anti–interleukin-5 (IL-5) monoclonal antibody developed by GSK, was associated with a sustained reduction in emergency department (ED) visits, hospitalisations, and symptom burden for ...